$428.59
2.72% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US45168D1046
Symbol
IDXX
Sector

IDEXX Laboratories Stock price

$428.59
-22.82 5.06% 1M
-87.91 17.02% 6M
-126.46 22.78% YTD
-51.04 10.64% 1Y
-193.86 31.14% 3Y
+176.72 70.16% 5Y
+354.53 478.71% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+11.35 2.72%
ISIN
US45168D1046
Symbol
IDXX
Sector

Key metrics

Market capitalization $35.09b
Enterprise Value $35.78b
P/E (TTM) P/E ratio 41.35
EV/FCF (TTM) EV/FCF 45.15
EV/Sales (TTM) EV/Sales 9.31
P/S ratio (TTM) P/S ratio 9.13
P/B ratio (TTM) P/B ratio 21.73
Revenue growth (TTM) Revenue growth 7.16%
Revenue (TTM) Revenue $3.84b
EBIT (operating result TTM) EBIT $1.11b
Free Cash Flow (TTM) Free Cash Flow $792.60m
Cash position $308.64m
EPS (TTM) EPS $10.36
P/E forward 41.01
P/S forward 9.05
EV/Sales forward 9.23
Short interest 3.26%
Show more

Create a Free Account to create an IDEXX Laboratories alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

IDEXX Laboratories Stock Analysis

Analyst Opinions

15 Analysts have issued a IDEXX Laboratories forecast:

6x Buy
40%
7x Hold
47%
2x Sell
13%

Analyst Opinions

15 Analysts have issued a IDEXX Laboratories forecast:

Buy
40%
Hold
47%
Sell
13%

Financial data from IDEXX Laboratories

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3,845 3,845
7% 7%
100%
- Direct Costs 1,510 1,510
4% 4%
39%
2,335 2,335
9% 9%
61%
- Selling and Administrative Expenses 883 883
14% 14%
23%
- Research and Development Expense 214 214
17% 17%
6%
1,238 1,238
5% 5%
32%
- Depreciation and Amortization 126 126
11% 11%
3%
EBIT (Operating Income) EBIT 1,112 1,112
4% 4%
29%
Net Profit 866 866
5% 5%
23%

In millions USD.

Don't miss a Thing! We will send you all news about IDEXX Laboratories directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEXX Laboratories Stock News

Neutral
Business Wire
5 days ago
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective June 1, 2025. Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance, will succeed Mr. McKeon as IDEXX's Executive Vice President, Chief Financial Offi...
Negative
Seeking Alpha
15 days ago
I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-int...
Neutral
The Motley Fool
20 days ago
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.
More IDEXX Laboratories News

Company Profile

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Head office United States
CEO Jonathan Mazelsky
Employees 11,000
Founded 1983
Website www.idexx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today